Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage strengths. The tablets can be used to treat both ALGS and PFIC in patients weighing 25kg or more who are able to swallow tablets.

The Food and Drug Administration (FDA) has approved a tablet formulation of Evrysdi ® (risdiplam) for the treatment of spinal muscular atrophy (SMA). Previously, the treatment had only been ...

The tablet formulation of zanubrutinib is now approved for all 5 indications across several hematological cancers, allowing patients to take 2 tablets rather than 4 capsules per day. | Image ...

FOSTER CITY, Calif., April 14, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet ...

In terms of functionality, commonly used superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate are effective at low concentration levels (2–5 w/w%) in tablet ...

This article describes the formulation of a tablet for a specific purpose, primarily using fractional or full factorial designs. The formulation work generated a matrix that was processed by two ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Below are some of the testing services newly introduced by CD Formulation: Tablet Fragility Test. The tablet fragility test is purposed to determine the resistance of tablets against mechanical stress ...

Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been approved by the US Food and Drug Administration (FDA). Evrysdi was originally ...

Mirum Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved a new tablet formulation of LIVMARLI ® for the treatment of cholestatic pruritus in patients ...